What to Expect From Medtronic Earnings

Photo of Trey Thoelcke
By Trey Thoelcke Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Medical device maker Medtronic PLC (NYSE: MDT) is scheduled to report its fiscal third-quarter results Tuesday before the opening bell. Thomson Reuters has consensus estimates of $0.97 in earnings per share (EPS) and $4.25 billion in revenue. In the same period of the previous year, the world’s third largest medical device company posted EPS of $0.91 and $4.16 million in revenue.

Since its tax-inversion merger with Covidien, announced last year and recently completed, Medtronic is headquartered in Dublin, Ireland, but it has operational headquarters in suburban Minneapolis. It products include everything from pacemakers to insulin pumps to surgical supplies.

The Covidien merger in 2014 has been the driver for Medtronic’s recent outperformance, and investors will be watching to see if that continues to be the case. Merrill Lynch included Medtronic among its top health care picks for 2015, citing the company’s relatively low-risk EPS growth outlook and potential for significant dividend growth.

Credit Suisse added Medtronic to its top picks list last year on the potential positive synergies resulting from the merger. Oppenheimer also saw Medtronic as a potential winner should the Republican-controlled Congress manage to repeal the medical device tax in the Affordable Care Act (ACA).

ALSO READ: 5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

The price-to-earnings (P/E) ratio at Medtronic is 26.08, which is less than its industry average. The price-to-book value on the stock is 3.79. The company has a market cap of around $74 billion, as well as dividend yield near 1.6%.

The 50-day moving average, currently at $73.71, has acted as support since before the merger was announced. The 200-day moving average is down at $66.51.

Shares ended last week at $75.26, up about 4.2% year to date. The stock has a consensus analyst price target of $82.28 and a 52-week trading range of $55.30 to $77.39.

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618